Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes
Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.
Weight Management | 16/10/2025 | By Dineshwori
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
Weight Management | 17/09/2025 | By Dineshwori | 134
Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies
Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.
Weight Management | 14/07/2025 | By Dineshwori | 165
Zealand Pharma and Roche to Develop and Commercialize Petrelintide
The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.
Weight Management | 15/03/2025 | By Aishwarya | 213
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy